Art. -Nr.: HY-B0148

Risedronic acid

(Synonyms: Risedronate)

2 Cited Publications

Kundenbewertung

Based on 2 publication(s) in Google Scholar

Risedronic acid (Risedronate) is a bisphosphonate and potent antiresorptive agent. Risedronic acid induces Apoptosis. Risedronic acid inhibits the transfer of farnesyl pyrophosphate groups to parasite proteins. Risedronic acid inhibits osteoclast-mediated bone resorption and alters bone metabolism. Risedronic acid inhibits blood-stage Plasmodium falciparum (IC₅₀ of 20.3 μM).

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.85%
CAS. Nr.: 105462-24-6
Formel: C₇H₁₁NO₇P₂
Molecular Weight:283.11

Speicherung:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)

Risedronic acid Chemical Structure

CAS. Nr.: 105462-24-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (2)
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle Parasite Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
13762	IC₅₀	>40 μM Compound: 1	Antiproliferative activity against rat 13762 cell line Antiproliferative activity against rat 13762 cell line	[PMID: 16970405]
HepG2	IC₅₀	16 μM Compound: Risedronate	Antimalarial activity against Plasmodium berghei NK65 infected in human HepG2 cells after 48 hrs by RT-PCR Antimalarial activity against Plasmodium berghei NK65 infected in human HepG2 cells after 48 hrs by RT-PCR	[PMID: 20457823]
HFF	IC₅₀	2.4 μM Compound: 6	In vitro inhibitory concentration against the growth of Toxoplasma gondii in human foreskin fibroblast monolayer cells (HFF cells) In vitro inhibitory concentration against the growth of Toxoplasma gondii in human foreskin fibroblast monolayer cells (HFF cells)	[PMID: 15857119]
JJN-3	EC₅₀	10 μM Compound: 2	Antiproliferative activity against human JJN-3 after 72 hrs by MTT assay Antiproliferative activity against human JJN-3 after 72 hrs by MTT assay	[PMID: 22390415]
KB	ED₅₀	255 μM Compound: 80	Dose to inhibit the growth of human KB carcinoma cell line Dose to inhibit the growth of human KB carcinoma cell line	[PMID: 16162013]
MCF7	IC₅₀	248 μM Compound: Risedronate	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 24 to 48 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 24 to 48 hrs by SRB assay	[PMID: 33132173]
MCF7	IC₅₀	35.7 μM Compound: 1	Antiproliferative activity against human MCF7 cell line by MTT assay Antiproliferative activity against human MCF7 cell line by MTT assay	[PMID: 16970405]
NCI-H460	IC₅₀	43.7 μM Compound: 1	Antiproliferative activity against human NCI-H460 cell line by MTT assay Antiproliferative activity against human NCI-H460 cell line by MTT assay	[PMID: 16970405]
RPMI-8226	EC₅₀	13 μM Compound: 2a	Cytotoxicity against human RPMI8226 cells after 72 hrs by MTT assay Cytotoxicity against human RPMI8226 cells after 72 hrs by MTT assay	[PMID: 23998921]
SF-268	IC₅₀	23.3 μM Compound: 1	Antiproliferative activity against human SF-268 cell line by MTT assay Antiproliferative activity against human SF-268 cell line by MTT assay	[PMID: 16970405]
T-cell	EC₅₀	5 μM Compound: 3	Effective concentration against human Gamma delta T cells Effective concentration against human Gamma delta T cells	[PMID: 15828834]
T-cell	IC₅₀	6.2 μM Compound: 8	Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using a constrained maximum TNF-alpha release of 2700 pg/mL Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using a constrained maximum TNF-alpha release of 2700 pg/mL	[PMID: 14711309]
T-cell	IC₅₀	6.9 μM Compound: 8	Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using individual observed maximum TNF-alpha release Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using individual observed maximum TNF-alpha release	[PMID: 14711309]
Vero	ED₅₀	55 μM Compound: 5	Antimicrobial activity against Trypanosoma cruzi CL amastigotes infected in african green monkey Vero cells measured on day 3 by fluorescence assay Antimicrobial activity against Trypanosoma cruzi CL amastigotes infected in african green monkey Vero cells measured on day 3 by fluorescence assay	[PMID: 24300918]
Vero	ED₅₀	55 μM Compound: Risedronate	Antiparasitic activity against Trypanosoma cruzi amastigotes infected in gamma-irradiated vero cells assessed as growth inhibition measured after 3 days by fluorescence assay Antiparasitic activity against Trypanosoma cruzi amastigotes infected in gamma-irradiated vero cells assessed as growth inhibition measured after 3 days by fluorescence assay	[PMID: 23318904]
Vero	IC₅₀	123 μM Compound: 2	Inhibition of Trypanosoma cruzi Amastigotes was determined in Vero cells culture and fetal calf serum Inhibition of Trypanosoma cruzi Amastigotes was determined in Vero cells culture and fetal calf serum	[PMID: 11300872]

In Vitro

Risedronic acid (0-10 μM; 14 days) suppresses the formation of mineralized nodules in human mesenchymal stem cells (hMSC12) and rat thymus-derived mesenchymal stem cells (ST1BIIb)^[1].
Risedronic acid (0-10 μM; 3 days) suppresses the mRNA expression of osteoblast marker gene osteocalcin (OC) in human mesenchymal stem cells (hMSC12)^[1].
Risedronic acid (100-1000 μM; 48 h) induces chromatin condensation and activates caspase-3 in human mesenchymal stem cells (hMSC12)^[1].
Risedronic acid (Risedronate) (15 μM; 36 h) inhibits isoprenoid biosynthesis in Plasmodium falciparum, as shown by the decreased intensities of bands corresponding to farnesol (FOH) and geranylgeraniol (GGOH)^[3].
Risedronic acid (15 μM; 36 h) interferes with protein isoprenylation in Plasmodium falciparum, reducing the intensities of farnesylated protein bands and increasing those of geranylgeranylated protein bands^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis¹

Cell Line:

Human mesenchymal stem cells (hMSC12)
Concentration:

100 μM, 300 μM, 500 μM, 1000 μM
Incubation Time:

48 h
Result:

Induced chromatin condensation and activated caspase-3.

In Vivo

Risedronic acid (Risedronate) (30 μg/kg; subcutaneous injection; once every other day; 3 weeks) prevents radiation-induced osteoporosis in female C57BL/6 mice irradiated with 2 Gy X-rays, inhibits trabecular bone loss and microstructural damage, and suppresses the increase in osteoclast number and serum TRAP5b^[2].
Risedronic acid (10-25 mg/kg; intraperitoneal injection; once a day; 7 days) inhibits parasitemia in BALB/c mice infected with Plasmodium berghei strain ANKA, but does not prolong the survival time of mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female C57BL/6 mice (20-week-old, ~23 g) irradiated with 2 Gy X-rays whole-body²
Dosage:

30 μg/kg
Administration:

Subcutaneous injection, once every other day, for 3 weeks
Result:

Prevented the radiation-induced increase in osteoclast number, surface, and TRAP5b.

Animal Model:

Male BALB/c mice (3-4 weeks old) infected with Plasmodium berghei strain ANKA by intraperitoneal injection of 1×10⁶ blood-stage parasites³
Dosage:

10 mg/kg, 15 mg/kg, 20 mg/kg, 25 mg/kg
Administration:

Intraperitoneal injection, once a day, for 7 days
Result:

Led to an 88.9% inhibition of the rodent parasite Plasmodium berghei in mice on the seventh day of treatment.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 105462-24-6
Appearance Solid
Molecular Weight 283.11
Formel C₇H₁₁NO₇P₂
Color White to off-white
SMILES

OC(P(O)(O)=O)(P(O)(O)=O)CC1=CN=CC=C1
Synonyms

Risedronate
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, sealed storage, away from moisture

* In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)

Publications (2)

All

Sort by:

Journal Impact Factor

Respir Res

Nebulization of risedronate alleviates airway obstruction and inflammation of chronic obstructive pulmonary diseases via suppressing prenylation-dependent RAS/ERK/NF-κB and RhoA/ROCK1/MLCP signaling. [Abstract]

2022 Dec 28;23(1):380. PMID: 36575527
Int J Parasitol Drugs Drug Resist

Promising efficacy of nitrogen-containing bisphosphonates against the infection of Cryptosporidium spp. [Abstract]

2025 Aug 6:29:100607. PMID: 40782657

Lösungsmittel & Löslichkeit

In Vitro:

0.1 M NaOH : 11 mg/mL (38.85 mM; ultrasonic and adjust pH to 7 with NaOH)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.5322 mL

17.6610 mL

35.3220 mL

5 mM

0.7064 mL

3.5322 mL

7.0644 mL

10 mM

0.3532 mL

1.7661 mL

3.5322 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (313 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Fujita H, et al. Effect of risedronate on osteoblast differentiation, expression of receptor activator of NF-κB ligand and apoptosis in mesenchymal stem cells. Basic Clin Pharmacol Toxicol. 2011 Aug;109(2):78-84. [Content Brief]

[2]. Willey JS, et al. Risedronate prevents early radiation-induced osteoporosis in mice at multiple skeletal locations. Bone. 2010 Jan;46(1):101-11. [Content Brief]

[3]. Jordao FM, et al. In vitro and in vivo antiplasmodial activities of risedronate and its interference with protein prenylation in Plasmodium falciparum. Antimicrob Agents Chemother. 2011 May;55(5):2026-31. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
0.1 M NaOH	1 mM	3.5322 mL	17.6610 mL	35.3220 mL	88.3049 mL
	5 mM	0.7064 mL	3.5322 mL	7.0644 mL	17.6610 mL
	10 mM	0.3532 mL	1.7661 mL	3.5322 mL	8.8305 mL
	15 mM	0.2355 mL	1.1774 mL	2.3548 mL	5.8870 mL
	20 mM	0.1766 mL	0.8830 mL	1.7661 mL	4.4152 mL
	25 mM	0.1413 mL	0.7064 mL	1.4129 mL	3.5322 mL
	30 mM	0.1177 mL	0.5887 mL	1.1774 mL	2.9435 mL

Keywords

Risedronic acid

2 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Risedronic acid

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

Publications Citing Use of MedChemExpress (MCE) Risedronic acid

Alle Parasite Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (2)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Risedronic acid

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

Publications Citing Use of MedChemExpress (MCE) Risedronic acid

Alle Parasite Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (2)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Risedronic acid Related Classifications

HY-B0148 Related Classifications